# ESPACOMP

# 15<sup>TH</sup> ANNUAL MEETING 2012 (OCTOBER 25 - 27, 2012 IN GHENT, BELGIUM) DETAILED PROGRAM

THURSDAY OCTOBER 25 (Adherence enhancing educational day)

Pre-conference adherence enhancing educational day on designing interventions for treatment initiation, execution and persistence (An Intervention Mapping Approach)

## Room Sint-Lucas

Coaches Marijn de Bruin, Marie Schneider, Gerjo Kok, Gjalt-Jorn Peters, Dilana Schaafsma

**Description** Intervention Mapping is one of the most frequently used and comprehensive frameworks for designing successful health behaviour change interventions. During this introductory workshop, participants will be introduced to the Intervention Mapping framework, relevant research methods and theories, and the core skills for designing health behaviour change interventions. This workshop will be applied to the field of medication adherence.

17.30 - 18.00	Translational moment summarising take-home messages and results of the case study of both educational days (room Sint-Lucas!)
16.30 - 17.00 17.00 - 17.30	E5 – Lecture 5 Intervention evaluation design Plenary discussion group work Challenges, outcomes, lessons
16.00 - 16.30	<b>Exercise 4</b> Define program materials and plan program adoption and delivery
15.30 - 16.00	<b>E4 – Lecture 4</b> Step 4 and 5: Designing program materials and Planning program delivery
15.00 - 15.30	Coffee break (at room Sint-Lucas)
13.30 – 14.15 14.15 – 15.00	<b>E3 – Lecture 3</b> Step 2: Setting program objectives and Step 3: Selecting theory- and evidence-based behaviour change methods <b>Exercise 3</b> Defining program objectives and selecting intervention methods and channel
12.30 – 13.30	Lunch break (room Kapittelzaal)
12.00 - 12.30	interventions Exercise 2 Building a theory- and evidence-based explanatory model of adherence
11.00 – 11.30 11.30 – 12.00	<b>Exercise 1</b> Collecting data from empirical literature for Needs Assessment <b>E2 – Lecture 2</b> Applying theory and evidence in health behaviour change
10.00 - 10.30 10.30 - 11.00	Welcome forming subgroups on adherence domain E1 – Lecture 1 Overview Intervention Mapping and Step 1: Conducting a needs assessment
09.00 09.30 – 10.00	Opening secretariat and reception of participants (at room Sint-Lucas) Welcome coffee (at room Sint-Lucas)

18.00 – 19.30 Academic showcase at Monasterium (room Kapittelzaal)

THURSDAY OCTOBER 25 (Patient adherence & drug development educational day)

Pre-conference patient adherence and drug development educational day on bridging the adherence gap between use-effectiveness and method-effectiveness

**Room** Sint-Marcus (and Sint-Lucas for the coffee breaks and translational moment) **Chairs** Luc Van Bortel and Bernard Vrijens

**Description** Contrary to the common belief, sub-optimal patient adherence prevails as well in clinical trials as in routine care. The usual result is unrecognized underdosing, that lowers the average effect of the test-drug and adds variability to its actions. When patient adherence to the test drug is not properly measured and managed in clinical trials, the statistical power of trials can be seriously undermined, resulting in a false negative conclusion about efficacy. Recent published analyses show that failure to prove efficacy is now the leading source of attrition In new drug development. Moreover, the extent of actual exposure of trial patients to the drug is underestimated by pre-electronic methods of assessing adherence. As a result, risk assessments are also underestimated. During this workshop, different approaches to these problems will be presented and discussed with experts from various backgrounds. The papers presented during this educational day will be invited for publication as a research topic in the journal called "Frontiers in Pharmacology" (www.frontiersin.org).

09.00 Opening secretariat and reception of participants (at room Sint-Lucas!) 09.30 – 10.00 Welcome coffee (at room Sint-Lucas!)

Welcome session

10.00 – 10.15 Introduction Luc Van Bortel and Bernard Vrijens

**10.15 – 10.30** Case study to be discussed throughout the day Robert Vander Stichele

Session 1 The problem of suboptimal patient adherence in clinical drug development and associated type II errors

10.30 – 10.45 Observed adherence in a data base of 17'000 pts from clinical studies Bernard Vrijens

- 10.45 11.15 What is the regulator perspective on the fact that there is evidence that non adherence is present in drug development studies but often non recognized by pill counting Bert Leufkens
- 11.15 11.30 Case study: 8 available dosing regimens: how best to pick the dose? Robert Vander Stichele

Session 2: The impact of variable adherence on studies of PK/PD

- 11:30 12:00 Concrete HIV examples of adherence impact in PK/PD Bernard Vrijens
- 12.00 12.15 Discussions moderated by Terry Blaschke
- 12.15 12.30 Case study: what is we brought PK variability in the decision process? Robert Vander Stichele
- 12.30 13.30 Lunch break (room Kapittelzaal)

Session 3: Modeling and Simulations based on actual vs assumed dosing history data

- 13.30 13.45 Introduction and definition on method effectiveness/comparative effectiveness/forgiveness John Urquhart
- 13.45 14.30 Method example difficulties how to do better Adam Lowy
- 14.30 14.45 Discussion moderated by John Urguhart
- 14.45 15.00 Case study: what if we brought adherence variability? R Vander Stichele
- 15.00 15.30 Coffee break (at room Sint-Lucas!)

Session 4: Strategies & tactics to deal with suboptimal adherence in clinical drug development

- 15.30 15.45 Presentation of the different strategies: measurement versus enhancing adherence in trials Ivo Abraham
- 15.45 16.30 Pharmacometric perspective justifying the need for dosing history data Lynn McFadyen
- 16.30 17.00 Discussion moderated by Ivo Abraham
- 17.00 17.30 Wrap-up of key messages & case study Luc Van Bortel & Robert Vander Stichele & Bernard Vrijens
- 17.30 18.00 Translational moment summarising take-home messages and results of the case study of both educational days (room Sint-Lucas!)
- 18.00 19.30 Academic showcase at Monasterium (room Kapittelzaal)

# FRIDAY OCTOBER 26

#### **Scientific meeting**

**Room** Sint Autbertuskerk (church) (for the lectures) and hall Kloostergang (for the coffee breaks, lunches and poster walk)

- 08.15 Opening secretariat and reception of participants (at hall Kloostergang in wing Maagdenvleugel)
  08.45 09.15 Welcome coffee (at hall Kloostergang in wing Maagdenvleugel)
  09.15 09.30 Welcome (Room Sint Autbertuskerk)
  09.30 10.30 F1 JM Métry lecture (Room Sint Autbertuskerk) Adherence to medications - Insights arising from studies on the unreliable link between prescribed and actual drug dosing histories Terrence Blaschke Chairs Robert Vander Stichele and Marcel Bouvy
   Description This presentation will discuss the importance of obtaining detailed dosing histories in clinical trials. In particular, the value of investigating the pharmaco-dynamics of suddenly stopping a drug or resuming drug dosing after a short drug holiday during pre-marketing clinical studies will be emphasized. Such information is important for inclusion in the post-marketing drug label, the
- 10.30 11.00 Coffee break (at hall Kloostergang in wing Maagdenvleugel)

Instructions for use by patients and physicians

11.00 – 12.30 F2 – Key lecture and selected abstracts (4) (Room Sint Autbertuskerk) Defining and expressing adherence Chairs Przemyslaw Kardas and Monique Elseviers

**Description** Researchers still lack agreement in their evaluation of patients' adherence. In field research, discussion focuses on how to handle detailed expressions of adherence such as 'incorrect timing of intake', 'missed doses', and 'drug holidays'. In contrast, database research mainly encounters problems about drug day coverage and overlap. This session aims to bridge the gap between field research and database research discussing strengths and limitations of both methodologies aiming to learn from each other and to achieve a more common way to approach adherence in the future.

11.00 – 11.30 Key lecture Robert Gross

Defining and expressing adherence: bridging the gap between field and database research

- **11.30 11.45 Oral presentation of selected abstract 1 (Veerle Foulon)** Adherence to oral anticancer drugs (OAD) in patients with metastatic renal cancer (MRCC): interim results of the prospective observational multicentre IPSOC study (investigating patient satisfaction with oral anticancer treatment)
- 11.45 12.00 Oral presentation of selected abstract 2 (Eline Tommelein) Medication adherence report scale (MARS-5) not valid as a quantitative measure of adherence to inhalation medication in patients with COPD
- 12.00 12.15 Oral presentation of selected abstract 3 (Yoleen Van Camp) Nurse-led interventions to enhance adherence to chronic medication: focus on methodological limitations for systematic review and meta-analysis
- 12.15 12.30 Oral presentation of selected abstract 4 (Marcia Vervloet) Variation in patients' adherence to oral antidiabetics: a multilevel analysis of electronic monitoring data

- 12.30 13.30 Lunch break (combined with poster session at hall Kloostergang)
- 13.15 14.00 F3 Poster session (Rooms Sanctus Augustinus, Erasmus and Ireneus) Conveners Monique Elseviers and Yoleen Van Camp
- 14.00 15.30 F4 Key lecture and selected abstracts (4) (Room Sint Autbertuskerk) Consequences of non-adherence Chairs Dyfrig Hughes and Eric Van Ganse

**Description** A lack of adequate adherence to appropriately prescribed medicines is recognised as one of the major factors contributing to therapeutic partial or non-response. The health and economic consequences are significant and warrants robust research to determine the implications for the effective and cost-effective use of medicines. Presentations in this session will focus on related methodological and applied research.

#### 14.00 – 14.30 Key lecture Mickael Hiligsmann

Clinical and economic consequences of non-adherence

- 14.30 14.45 Oral presentation of selected abstract 1 (Edwin Oberjé) Cost-effectiveness of medication adherence enhancing interventions: a systematic review
- 14.45 15.00 Oral presentation of selected abstract 2 (Hanna Burkhalter) Daytime sleepiness is associated with immunosupressive nonadherence in renal transplant patients
- 15.00 15.15 Oral presentation of selected abstract 3 (Cecile Goujard) Simultaneity and adherence to multiple tablet regimen among HIV-infected patients starting once-daily Atazanavir/Ritonavir (ATV/RTV)-based therapy: the ANRS 134 – COPHAR 3 trial
- **15.15 15.30** Oral presentation of selected abstract 4 (Ivo Abraham) No margin for nonadherence: novel application of Kaplan-Meier methods to model the efficacy of adherence to Imatinib treatment by patients with chronic myeloid leukemia (the ADAGIO study)
- 15.30 16.00 Coffee break (at hall Kloostergang in wing Maagdenvleugel)

16.00 – 17.30 F5 – Key lecture and selected abstracts (4) (Room Sint Autbertuskerk) Adherence interventions (behavioural) Chairs Sabina De Geest and Marijn de Bruin

**Description** Better approaches towards the development, implementation en evaluation of adherence interventions is a major priority in the field as the evidence base needs to be strengthened. In this session the methodologically sound development of adherence interventions will be discussed and research focusing on designing, implementing and testing of adherence interventions will be presented.

# 16.00 – 16.30 Key lecture Gerjo Kok

Understanding and changing treatment adherence

- 16.30 16.45 Oral presentation of selected abstract 1 (Isabelle Menetrey) Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with Cinacalcet: results of a prospective randomized controlled study
- **16.45 17.00** Oral presentation of selected abstract 2 (Petra Denig) The relationship between medication beliefs and intentional versus unintensional nonadherence to glucose-lowering, antihypertensive, and lipid-lowering drugs
- 17.00 17.15 Oral presentation of selected abstract 3 (Mallory Johnson) Advances in the conceptualization and measurement of health care empowerment: linkages to HIV treatment adherence and clinical outcomes
- 17.15 17.30 Oral presentation of selected abstract 4 (Hans Wouters) Examination of women's perceptions and experiences with regard to adjuvant endocrine treatment of breast cancer: overview and associations with nonadherence
- 17.30 18.30ESPACOMP Board meeting (Room Huiskapel)18.30Evening event: guided boat trip with dinner

# **SATURDAY OCTOBER 27**

#### Scientific meeting

### Room Sint Lucas

08.30	Opening secretariat and reception of participants
08.30 - 09.00	Welcome coffee

## 09.00 – 10.30 S1 – Key lecture and selected abstracts (4) Adherence support through innovative technologies Chairs Rob Heerdink and Kurt Hersberger

**Description** Development of information technologies, new packaging inventions and the combination of both open a wide field for new potential solutions to support patients with respect to unintentional non-adherence. Furthermore, these new technologies may also enable new approaches to monitor patient adherence. What are the first experiences and what can we expect in the near future?

- 09.00 09.20 Key lecture Tassilo Korab

   Overview of innovative technologies to support patient adherence
   09.20 09.35 Oral presentation of selected abstract 1 (Sabina De Geest) Wireless detection of drug intake for monitoring treatment adherence in renal transplant patients
   09.35 09.50 Oral presentation of selected abstract 2 (Isabelle Arnet)
  - First validation data of the new polymedication electronic monitoring system (POEMS)
- 09.50 10.05 Oral presentation of selected abstract 3 (R Oosterom-Calo) Development of a computer-tailored medication adherence promotion program for heart failure patients
- 10.05 10.20 Oral presentation of selected abstract 4 (Marcel Kooij) A community pharmacist-led intervention to improve adherence to lipid-lowering treatment by counselling and an electronic reminder device: results of a randomized controlled trial in the Netherlands
- 10.30 11.00 Coffee break

# 11.00 – 12.30 S2 – Key lecture and panel discussion

Chairs Robert Vander Stichele and John Urquhart

**Description** In the panel session, led by Ivo Abraham, possible directions for future adherence research will be discussed with the keynote lecturers of the different sessions of the meeting. An overview will be given of objectives and funding criteria of current and comming research programs at the European and global level. The panel will discuss recommendations for integration of adherence research in drug development and applying expertise in behavioral interventions for maximization of adherence in real life clinical practice.

11.00 – 11.30 Key lecture lvo Abraham

Adherence research: Stick to the past or jump to the future?

11.30 – 12.30 Panel discussion

Terrence Blaschke, Tassilo Korab, Mickael Hiligsmann, Ivo Abraham, Bernard Vrijens, Marijn de Bruin and Robert Gross